We are analyzing https://link.springer.com/article/10.1007/s11864-023-01161-5.

Title:
Treatment Landscape of Renal Cell Carcinoma | Current Treatment Options in Oncology
Description:
The treatment landscape of renal cell carcinoma (RCC) has evolved significantly over the past three decades. Active surveillance and tumor ablation are alternatives to extirpative therapy in appropriately selected patients. Stereotactic body radiation therapy (SBRT) is an emerging noninvasive alternative to treat primary RCC tumors. The advent of immune checkpoint inhibitors (ICIs) has greatly improved the overall survival of advanced RCC, and now the ICI-based doublet (dual ICI-ICI doublet; or ICI in combination with a vascular endothelial growth factor tyrosine kinase inhibitor, ICI-TKI doublet) has become the standard frontline therapy. Based on unprecedented outcomes in the metastatic with ICIs, they are also being explored in the neoadjuvant and adjuvant setting for patients with high-risk disease. Adjuvant pembrolizumab has proven efficacy to reduce the risk of RCC recurrence after nephrectomy. Historically considered a radioresistant tumor, SBRT occupies an expanding role to treat RCC with oligometastasis or oligoprogression in combination with systemic therapy. Furthermore, SBRT is being investigated in combination with ICI-doublet in the advanced disease setting. Lastly, given the treatment paradigm is shifting to adopt ICIs at earlier disease course, the prospective studies guiding treatment sequencing in the post-ICI setting is maturing. The effort is ongoing in search of predictive biomarkers to guide optimal treatment option in RCC.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We find it hard to spot revenue streams.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Link.springer.com has a revenue plan, but it's either invisible or we haven't found it.

Keywords {🔍}

patients, renal, pubmed, cell, article, carcinoma, google, scholar, rcc, months, phase, therapy, study, trial, risk, cas, advanced, disease, oncol, cancer, pfs, treatment, efficacy, median, imdc, ipilimumabnivolumab, ici, combination, sunitinib, central, cabozantinib, metastatic, setting, adjuvant, pembrolizumab, orr, nivolumab, clin, followup, trials, icitki, nephrectomy, sbrt, investigated, results, localized, table, monotherapy, benefit, favorable,

Topics {✒️}

high-risk renal-cell carcinoma prior anti-pd-1/pd-l1 regimens met/vegf/axl/ret/kit multi-center single-arm study metastatic renal-cell carcinoma metastatic renal-cell carcinoma metastatic renal-cell cancer advanced renal-cell carcinoma article download pdf exhibit primary resistance improved therapeutic options prior pd-1/pd-l1 inhibitors interferon-alfa-based immunotherapy compared hemoglobin/neutrophil/platelet/calcium vegfr-tyrosine kinase inhibitors treated-related adverse events unnecessary treatment-related toxicity important single-arm study dual ici-ici treatments contemporary ici-based regimens met proto-oncogene alterations renal cell carcinoma renal-cell carcinoma fumarate hydratase-deficient rcc succinate dehydrogenase-deficient rcc favors ici-tki combinations previously ici-treated mccrcc long-term durable response robot-assisted partial nephrectomy dual ici-ici combination single-arm study demonstrated rini bi demonstrated anti-tumor activity anti-tumor immune response dual ici-ici doublet aforementioned ici-doublet trials shared-decision making process interferon alfa-2b compared ici-tki combinations generally previous anti-vegf therapies imdc intermediate/poor risk aditya bagrodia reported brent rose md advanced renal cancer durable long-term efficacy ici-tki combinations specifically motzer rj frontline ici-based doublets improved disease-free survival prior ici-tki combination

Questions {❓}

Adjuvant therapy in renal cell carcinoma: are we ready for prime time?
Is robotic partial nephrectomy safe for T3a renal cell carcinoma?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Treatment Landscape of Renal Cell Carcinoma
         description:The treatment landscape of renal cell carcinoma (RCC) has evolved significantly over the past three decades. Active surveillance and tumor ablation are alternatives to extirpative therapy in appropriately selected patients. Stereotactic body radiation therapy (SBRT) is an emerging noninvasive alternative to treat primary RCC tumors. The advent of immune checkpoint inhibitors (ICIs) has greatly improved the overall survival of advanced RCC, and now the ICI-based doublet (dual ICI-ICI doublet; or ICI in combination with a vascular endothelial growth factor tyrosine kinase inhibitor, ICI-TKI doublet) has become the standard frontline therapy. Based on unprecedented outcomes in the metastatic with ICIs, they are also being explored in the neoadjuvant and adjuvant setting for patients with high-risk disease. Adjuvant pembrolizumab has proven efficacy to reduce the risk of RCC recurrence after nephrectomy. Historically considered a radioresistant tumor, SBRT occupies an expanding role to treat RCC with oligometastasis or oligoprogression in combination with systemic therapy. Furthermore, SBRT is being investigated in combination with ICI-doublet in the advanced disease setting. Lastly, given the treatment paradigm is shifting to adopt ICIs at earlier disease course, the prospective studies guiding treatment sequencing in the post-ICI setting is maturing. The effort is ongoing in search of predictive biomarkers to guide optimal treatment option in RCC.
         datePublished:2023-12-28T00:00:00Z
         dateModified:2023-12-28T00:00:00Z
         pageStart:1889
         pageEnd:1916
         license:http://creativecommons.org/licenses/by/4.0/
         sameAs:https://doi.org/10.1007/s11864-023-01161-5
         keywords:
            Renal cell carcinoma
            Immunotherapy
            Immune checkpoint inhibitor
            Kidney cancer
            Oncology
         image:
         isPartOf:
            name:Current Treatment Options in Oncology
            issn:
               1534-6277
               1527-2729
            volumeNumber:24
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Yu-Wei Chen
               affiliation:
                     name:University of California San Diego
                     address:
                        name:Division of Hematology Oncology, University of California San Diego, San Diego, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Luke Wang
               affiliation:
                     name:University of California San Diego
                     address:
                        name:Department of Urology, University of California San Diego, San Diego, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Justine Panian
               affiliation:
                     name:University of California San Diego
                     address:
                        name:School of Medicine, University of California San Diego, San Diego, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sohail Dhanji
               affiliation:
                     name:The University of Tennessee Health Science Center
                     address:
                        name:Department of Urology, The University of Tennessee Health Science Center, Memphis, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ithaar Derweesh
               affiliation:
                     name:University of California San Diego
                     address:
                        name:Department of Urology, University of California San Diego, San Diego, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Brent Rose
               affiliation:
                     name:University of California San Diego
                     address:
                        name:Department of Radiation Oncology, University of California San Diego, San Diego, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Aditya Bagrodia
               affiliation:
                     name:University of California San Diego
                     address:
                        name:Department of Urology, University of California San Diego, San Diego, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Rana R. McKay
               affiliation:
                     name:University of California San Diego
                     address:
                        name:Division of Hematology Oncology, University of California San Diego, San Diego, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Treatment Landscape of Renal Cell Carcinoma
      description:The treatment landscape of renal cell carcinoma (RCC) has evolved significantly over the past three decades. Active surveillance and tumor ablation are alternatives to extirpative therapy in appropriately selected patients. Stereotactic body radiation therapy (SBRT) is an emerging noninvasive alternative to treat primary RCC tumors. The advent of immune checkpoint inhibitors (ICIs) has greatly improved the overall survival of advanced RCC, and now the ICI-based doublet (dual ICI-ICI doublet; or ICI in combination with a vascular endothelial growth factor tyrosine kinase inhibitor, ICI-TKI doublet) has become the standard frontline therapy. Based on unprecedented outcomes in the metastatic with ICIs, they are also being explored in the neoadjuvant and adjuvant setting for patients with high-risk disease. Adjuvant pembrolizumab has proven efficacy to reduce the risk of RCC recurrence after nephrectomy. Historically considered a radioresistant tumor, SBRT occupies an expanding role to treat RCC with oligometastasis or oligoprogression in combination with systemic therapy. Furthermore, SBRT is being investigated in combination with ICI-doublet in the advanced disease setting. Lastly, given the treatment paradigm is shifting to adopt ICIs at earlier disease course, the prospective studies guiding treatment sequencing in the post-ICI setting is maturing. The effort is ongoing in search of predictive biomarkers to guide optimal treatment option in RCC.
      datePublished:2023-12-28T00:00:00Z
      dateModified:2023-12-28T00:00:00Z
      pageStart:1889
      pageEnd:1916
      license:http://creativecommons.org/licenses/by/4.0/
      sameAs:https://doi.org/10.1007/s11864-023-01161-5
      keywords:
         Renal cell carcinoma
         Immunotherapy
         Immune checkpoint inhibitor
         Kidney cancer
         Oncology
      image:
      isPartOf:
         name:Current Treatment Options in Oncology
         issn:
            1534-6277
            1527-2729
         volumeNumber:24
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Yu-Wei Chen
            affiliation:
                  name:University of California San Diego
                  address:
                     name:Division of Hematology Oncology, University of California San Diego, San Diego, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Luke Wang
            affiliation:
                  name:University of California San Diego
                  address:
                     name:Department of Urology, University of California San Diego, San Diego, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Justine Panian
            affiliation:
                  name:University of California San Diego
                  address:
                     name:School of Medicine, University of California San Diego, San Diego, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sohail Dhanji
            affiliation:
                  name:The University of Tennessee Health Science Center
                  address:
                     name:Department of Urology, The University of Tennessee Health Science Center, Memphis, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ithaar Derweesh
            affiliation:
                  name:University of California San Diego
                  address:
                     name:Department of Urology, University of California San Diego, San Diego, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Brent Rose
            affiliation:
                  name:University of California San Diego
                  address:
                     name:Department of Radiation Oncology, University of California San Diego, San Diego, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Aditya Bagrodia
            affiliation:
                  name:University of California San Diego
                  address:
                     name:Department of Urology, University of California San Diego, San Diego, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Rana R. McKay
            affiliation:
                  name:University of California San Diego
                  address:
                     name:Division of Hematology Oncology, University of California San Diego, San Diego, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Current Treatment Options in Oncology
      issn:
         1534-6277
         1527-2729
      volumeNumber:24
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of California San Diego
      address:
         name:Division of Hematology Oncology, University of California San Diego, San Diego, USA
         type:PostalAddress
      name:University of California San Diego
      address:
         name:Department of Urology, University of California San Diego, San Diego, USA
         type:PostalAddress
      name:University of California San Diego
      address:
         name:School of Medicine, University of California San Diego, San Diego, USA
         type:PostalAddress
      name:The University of Tennessee Health Science Center
      address:
         name:Department of Urology, The University of Tennessee Health Science Center, Memphis, USA
         type:PostalAddress
      name:University of California San Diego
      address:
         name:Department of Urology, University of California San Diego, San Diego, USA
         type:PostalAddress
      name:University of California San Diego
      address:
         name:Department of Radiation Oncology, University of California San Diego, San Diego, USA
         type:PostalAddress
      name:University of California San Diego
      address:
         name:Department of Urology, University of California San Diego, San Diego, USA
         type:PostalAddress
      name:University of California San Diego
      address:
         name:Division of Hematology Oncology, University of California San Diego, San Diego, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Yu-Wei Chen
      affiliation:
            name:University of California San Diego
            address:
               name:Division of Hematology Oncology, University of California San Diego, San Diego, USA
               type:PostalAddress
            type:Organization
      name:Luke Wang
      affiliation:
            name:University of California San Diego
            address:
               name:Department of Urology, University of California San Diego, San Diego, USA
               type:PostalAddress
            type:Organization
      name:Justine Panian
      affiliation:
            name:University of California San Diego
            address:
               name:School of Medicine, University of California San Diego, San Diego, USA
               type:PostalAddress
            type:Organization
      name:Sohail Dhanji
      affiliation:
            name:The University of Tennessee Health Science Center
            address:
               name:Department of Urology, The University of Tennessee Health Science Center, Memphis, USA
               type:PostalAddress
            type:Organization
      name:Ithaar Derweesh
      affiliation:
            name:University of California San Diego
            address:
               name:Department of Urology, University of California San Diego, San Diego, USA
               type:PostalAddress
            type:Organization
      name:Brent Rose
      affiliation:
            name:University of California San Diego
            address:
               name:Department of Radiation Oncology, University of California San Diego, San Diego, USA
               type:PostalAddress
            type:Organization
      name:Aditya Bagrodia
      affiliation:
            name:University of California San Diego
            address:
               name:Department of Urology, University of California San Diego, San Diego, USA
               type:PostalAddress
            type:Organization
      name:Rana R. McKay
      affiliation:
            name:University of California San Diego
            address:
               name:Division of Hematology Oncology, University of California San Diego, San Diego, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Division of Hematology Oncology, University of California San Diego, San Diego, USA
      name:Department of Urology, University of California San Diego, San Diego, USA
      name:School of Medicine, University of California San Diego, San Diego, USA
      name:Department of Urology, The University of Tennessee Health Science Center, Memphis, USA
      name:Department of Urology, University of California San Diego, San Diego, USA
      name:Department of Radiation Oncology, University of California San Diego, San Diego, USA
      name:Department of Urology, University of California San Diego, San Diego, USA
      name:Division of Hematology Oncology, University of California San Diego, San Diego, USA

External Links {🔗}(319)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.5s.

LINK . SPRINGER . COM {}